Evidence map›Paper›PMID 34080613›Full record

ArticleCerebral cortex (New York, N.Y. : 1991)2021

Resting-State Network Alterations Differ between Alzheimer's Disease Atrophy Subtypes.

Boris-Stephan Rauchmann, Ersin Ersoezlue, Sophia Stoecklein, Daniel Keeser, Frederic Brosseron, Katharina Buerger, Peter Dechent, Laura Dobisch, Birgit Ertl-Wagner, Klaus Fliessbach and 27 more

Abstract read
In one paragraph

Article in Cerebral cortex (New York, N.Y. : 1991), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Altered intrinsic ignition dynamics linked to Amyloid-bioRxiv : the preprint server for biology · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Recent update on the heterogeneity of the Alzheimer's disease spectrum.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Boris-Stephan RauchmannDepartment of Radiology, University Hospital, LMU, Munich 81377, Germany.
Ersin ErsoezlueDepartment of Psychiatry and Psychotherapy, University Hospital, LMU, Munich 80336, Germany.
Sophia StoeckleinDepartment of Radiology, University Hospital, LMU, Munich 81377, Germany.
Daniel KeeserDepartment of Radiology, University Hospital, LMU, Munich 81377, Germany.
Frederic BrosseronGerman Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.
Katharina BuergerGerman Center for Neurodegenerative Diseases (DZNE), Munich 81377, Germany.
Peter DechentMR-Research in Neurology and Psychiatry, Georg-August-University Goettingen, Göttingen 37077, Germany.
Laura DobischGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg 39120, Germany.
Birgit Ertl-WagnerDepartment of Radiology, University Hospital, LMU, Munich 81377, Germany.
Klaus FliessbachGerman Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.
John Dylan HaynesBernstein Center for Computational Neuroscience, Charité, Berlin 10115, Germany.
Michael T HenekaGerman Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.
Enise I IncesoyGerman Center for Neurodegenerative Diseases (DZNE), Berlin 10117, Germany.
Daniel JanowitzInstitute for Stroke and Dementia Research (ISD), University Hospital, LMU, Munich 81377, Germany.
Ingo KilimannGerman Center for Neurodegenerative Diseases (DZNE), Rostock 18147, Germany.
Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), Tuebingen 72076, Germany.
Coraline D MetzgerGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg 39120, Germany.
Matthias H MunkGerman Center for Neurodegenerative Diseases (DZNE), Tuebingen 72076, Germany.
Oliver PetersGerman Center for Neurodegenerative Diseases (DZNE), Berlin 10117, Germany.
Josef PrillerGerman Center for Neurodegenerative Diseases (DZNE), Berlin 10117, Germany.
Alfredo RamirezGerman Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.
Sandra RoeskeGerman Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.
Nina RoyGerman Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.
Klaus SchefflerDepartment for Biomedical Magnetic Resonance, University of Tuebingen, Tuebingen 72076, Germany.
Anja SchneiderGerman Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.
Annika SpottkeGerman Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.
Eike Jakob SpruthGerman Center for Neurodegenerative Diseases (DZNE), Berlin 10117, Germany.
Stefan TeipelGerman Center for Neurodegenerative Diseases (DZNE), Rostock 18147, Germany.
Maike TscheuschlerDepartment of Psychiatry, University of Cologne, Medical Faculty, Cologne 50924, Germany.
Ruth VukovichDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen 37075, Germany.
Michael WagnerGerman Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.
Jens WiltfangDepartment of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen 37075, Germany.
Renat YakupovGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg 39120, Germany.
Emrah DuezelGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg 39120, Germany.
Frank JessenGerman Center for Neurodegenerative Diseases (DZNE), Bonn 53127, Germany.
Robert PerneczkyDepartment of Psychiatry and Psychotherapy, University Hospital, LMU, Munich 80336, Germany.
DELCODE study group and the Alzheimer's Disease Neuroimaging Initiative (ADNI)

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Alzheimer's Drug Discovery FoundationAmorfix Life Sciences LtdBayer HealthCareCIHRNIA NIH HHS U01 AG024904NIBIB NIH HHSTakeda Pharmaceutical Company
6 · The paper itself

Abstract

Several Alzheimer's disease (AD) atrophy subtypes were identified, but their brain network properties are unclear. We analyzed data from two independent datasets, including 166 participants (103 AD/63 controls) from the DZNE-longitudinal cognitive impairment and dementia study and 151 participants (121 AD/30 controls) from the AD neuroimaging initiative cohorts, aiming to identify differences between AD atrophy subtypes in resting-state functional magnetic resonance imaging intra-network connectivity (INC) and global and nodal network properties. Using a data-driven clustering approach, we identified four AD atrophy subtypes with differences in functional connectivity, accompanied by clinical and biomarker alterations, including a medio-temporal-predominant (S-MT), a limbic-predominant (S-L), a diffuse (S-D), and a mild-atrophy (S-MA) subtype. S-MT and S-D showed INC reduction in the default mode, dorsal attention, visual and limbic network, and a pronounced reduction of "global efficiency" and decrease of the "clustering coefficient" in parietal and temporal lobes. Despite severe atrophy in limbic areas, the S-L exhibited only marginal global network but substantial nodal network failure. S-MA, in contrast, showed limited impairment in clinical and cognitive scores but pronounced global network failure. Our results contribute toward a better understanding of heterogeneity in AD with the detection of distinct differences in functional connectivity networks accompanied by CSF biomarker and cognitive differences in AD subtypes.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAtrophyBrainHumansMagnetic Resonance ImagingAlzheimer’s diseasebrain structuregraph theoryindependent component analysisresting-state connectivity

Identifiers

PMID34080613
PMCPMC8491689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.